NYC-based Rgenix raises $33 million to advance cancer immunotherapy

The biotech hopes to start Phase 1 testing on the drug this fall. 

By Nicole Gray • June 15, 2016

Lilly and Boehringer's Jardiance sets new bar, shows kidney benefit

Other drugmakers have rushed to match the drug's previously proven cardiovascular benefit, but new data shows it can help slow the progression of kidney disease. 

By Nicole Gray • June 15, 2016

Explore the Trendline➔

Neuroscience drug development

Enthusiasm is running higher among drugmakers and investors for neuroscience drug development, buoyed by recent approvals of new Alzheimer’s, ALS and depression medicines.

By BioPharma Dive staff

Teva hands back global rights for heart drug to Australian Mesoblast

Mesoblast will now have to fund Phase 3 development of the drug without a major partner. 

By Nicole Gray • June 15, 2016

Infinity Pharma to lay off one-fifth of staff in wake of phase 2 setback

Markets reacted sharply, with Infinity stock dropping in value by nearly 72% Tuesday. 

By Nicole Gray • June 14, 2016

Merck eyes US approval with positive data on Lantus copy

Similar to Eli Lilly's recently approved Basaglar, Merck is developing MK-1293 as a "follow-on biologic" to Sanofi's insulin glargine. 

By Nicole Gray • June 14, 2016

Novo's diabetes drug shown to decrease heart risks, boosting competitive edge

Victoza is only the second drug for the metabolic condition to demonstrate a cardiovascular benefit. 

By Nicole Gray • June 14, 2016

Merck, Pfizer expand trial studying CV benefit of experimental diabetes drug

The companies recently announced the drug, ertugliflozin, had met its primary endpoints in two phase 3 trials. 

By Nicole Gray • June 13, 2016

Sanofi's diabetes drug hits trial targets, heads for final approval

A FDA vote on LixiLan is expected in August.

By Randy Lilleston • June 13, 2016

Lilly presents solid long-term data for baricitinib in RA patients

The patients experienced significantly significant improvements in pain, fatigue, physical function and physical health-related quality of life.

By Nicole Gray • June 12, 2016

Amgen's chronic migraine-prevention drug shows promise in midstage trials

Alder Biopharmaceuticals, Lilly and Teva are also at work on chronic-migraine drugs that target the CGRP receptor. 

By Nicole Gray • June 10, 2016

Study: Blood-based 'liquid biopsy' cancer testing works

A study that included genetic information from 15,000 patients across 50 tumor types confirmed the accuracy of the tests for diagnostic and tumor-tracking purposes. 

By Nicole Gray • June 8, 2016

Kite, Juno anticipating 2017 approvals for T-cell therapy

The two companies, both recognized CAR-T front-runners, are aiming for FDA approvals for treatment of blood cancers by next year.  

By Nicole Gray • June 8, 2016

Biogen's MS drug fails phase 2 trial

Biogen says that it has seen evidence of the drug's clinical effect and will further analyze data for a path forward. 

By Shalina Chatlani • June 8, 2016

Small biotech Accera reinvents itself, takes aim at Alzheimer's treatment

BioPharma Dive spoke to Charles Stacey, CEO of Accera, about its ongoing Phase 3 study for a new kind of Alzheimer's drug. 

By Ned Pagliarulo • June 8, 2016

Alexion's Soliris fails in late-stage myasthenia gravis trial

The treatment generated $2.59 billion in sales last year. 

By Nicole Gray • June 7, 2016

FDA asks Sarepta for more data on muscular dystrophy drug

Shares of Sarepta jumped 25% higher in late trading Monday, as investors continue to hope for a path to approval for eteplirsen. 

By Ned Pagliarulo • June 7, 2016

Regeneron/Sanofi's dupilumab shines in phase 3 eczema trial

Analysts are looking for up to $2.5 billion in peak sales for dupilumab. 

By Nicole Gray • June 6, 2016

Study: Bristol-Myers' immunotherapy combo boosts response in lung cancer

Previous studies of Opdivo and Yervoy administered together had shown benefit in treating melanoma. 

By Nicole Gray • June 6, 2016

Roche positioning Tecentriq as first-line therapy in bladder cancer

It is the first new therapy approved for bladder cancer in 30 years. 

By Nicole Gray • June 6, 2016

Mylan's Herceptin biosim shows comparable efficacy/safety

There has not been one biosimilar approved in the EU or the U.S. to treat cancer. 

By Nicole Gray • June 6, 2016

AbbVie lung cancer drug shows promise, but has high expectations to meet

The drug, called Rova-T, was acquired by AbbVie earlier this year after its acquisition of Stemcentrx. 

By Ned Pagliarulo • June 5, 2016

Global cancer drug spending rises, set to surpass $150 billion by 2020

A wave of new drugs entering the market over the past five years has helped drive spending higher, according to a new report from IMS Health.

By Ned Pagliarulo • June 2, 2016

Kite Pharma rides CAR-T momentum into ASCO

BioPharma Dive spoke to the immuno-oncology biotech to find out how its lead cell therapy is progressing as it aims for a 2017 launch.

By Nicole Gray • June 2, 2016

Daiichi Sankyo halts late-stage study of lung cancer drug

But the company stood by the underlying science of patritumab and said it would press forward with development in head and neck cancers. 

By Nicole Gray • June 1, 2016

BioMarin ends Duchenne program, withdraws EU application for drisapersen

The decision brings BioMarin's current Duchenne program to a close, two years after the company paid $680 million to acquire Prosensa for rights to drisapersen.

By Ned Pagliarulo • May 31, 2016